MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • AMRI Molecular Research, Inc. (AMRI) Expands Drug Discovery Research Operations In India 0 comments
    Jun 19, 2012 2:09 PM | about stocks: AMRI

    AMRI, which was founded in 1991 as Albany Molecular Research, Inc., is a global contract research and manufacturing company offering its customers fully integrated drug discovery, development, and manufacturing services. The company, with a track record of success spanning over 21 years, has locations in the United States, Europe, and Asia to serve its customers.

    The company announced today the hiring of two experts in medicinal and computational chemistry at its research center located at Hyderabad, India. It also announced the completion of the relocation of custom library synthesis resources and capabilities to Hyderabad from its Budapest, Hungary facilities. These two events will provide AMRI additional flexibility to enhance productivity and client service for its global drug discovery operations.

    The two new hires are Dr. Srinivas Nanduri, Ph.D. and Dr. Suneel Kumar Bommisetty, Ph.D. Dr. Nanduri was hired as director of Medicinal chemistry in India while Dr. Bommisetty was hired as senior research associate of computational chemistry and will report to Dr. Nanduri. Dr. Nanduri reports directly to the president of India operations, Subramanyam Maddala. These two newly created positions are expected to strengthen AMRI's capabilities in problem solving medicinal chemistry.

    Both new hires bring a high level of medicinal chemistry expertise, drug discovery project management experience, and a strong track record of industry expertise. Dr. Nanduri's most recent role was research director at Aurigene where he was responsible for execution of supervision of multiple integrated drug discovery projects. He also worked previously at Biocon-BMS Research Center and at one of India's leading pharmaceutical companies, Dr. Reddy's Laboratories. Dr. Bommisetty joins the firm from GVK Biosciences and brings more than eight years of computational chemistry experience.

    For additional information about AMRI, please visit the company's website at www.amriglobal.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: AMRI
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.